Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Odevixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 2/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odevixibat SCHEMBL946468 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL25794588 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL17733623 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL31121705 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL16414427 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL20260213 | 0.99 | NR1H4 (0.98) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL4566711 | 0.96 | NR1H4 (0.93) | NR1H4SLC10A2 | |
| SCHEMBL19046549 | 0.96 | NR1H4 (0.93) | NR1H4SLC10A2 | |
| SCHEMBL918882 | 0.96 | NR1H4 (0.93) | NR1H4SLC10A2 | |
| SCHEMBL2697206 | 0.96 | NR1H4 (0.92) | NR1H4KMT2AATMSLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-10221212-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2019-03-05 | — | — | US | disclosed |
| US-20170182059-A1 | IBAT Inhibitors for the Treatment of Liver Disease | ALBIREO AB (SE) | 2017-06-29 | — | — | US | disclosed |
| US-20170182115-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221212-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | SLC10A2 3/4885NR1H4 46/4885KMT2A 1882/4885 |
| US-20170182115-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | SLC10A2, GIPR, GPBAR1 | SLC10A2 1/4885NR1H4 8/4885KMT2A 3354/4885 |
| US-20170182059-A1 | IBAT Inhibitors for the Treatment of Liver Disease | SLC10A2, SLC10A1, GPR119 | SLC10A2 1/4885NR1H4 50/4885KMT2A 1853/4885 |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885NR1H4 3/4885KMT2A 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.